Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

Clinical trial NCT06475196 · UNKNOWN

Trial details

NCT number: NCT06475196
Sponsor: Tang-Du Hospital
Status: UNKNOWN
Study type: OBSERVATIONAL

Resectable Esophageal Squamous Cell Carcinoma

Start date: 2024-06-20
Primary completion: 2024-06-20
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.